<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678753</url>
  </required_header>
  <id_info>
    <org_study_id>YKP3089C025</org_study_id>
    <nct_id>NCT03678753</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is intended to study the safety and effectiveness of an new anti-epileptic drug&#xD;
      (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures. Eligible Subjects will continue to&#xD;
      take their usual AEDs and receive either cenobamate or placebo. Subjects will have a 50%&#xD;
      chance or receiving cenobamate or placebo (sugar pill). Subjects will initially receive 12.5&#xD;
      mg of cenobamate or placebo (study drug) and increase the dose every two weeks until they&#xD;
      reach a target dose of 200 mg. Subjects will take study drug at approximately the same time&#xD;
      in the morning (once a day) with or without food. If tolerability issues arise, dosing can be&#xD;
      changed to evening. Also, once a subject reaches 200 mg of study drug, the dose can be&#xD;
      decreased one time to 150 mg, if necessary. The treatment period is 22 weeks and there is a 3&#xD;
      week follow up period, which includes a one week decrease in study drug to 100 mg prior to&#xD;
      stopping. Subjects who complete may be eligible for an extension study and will not have to&#xD;
      complete the follow up period. Subjects will track their seizure types and frequency in a&#xD;
      diary throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, placebo controlled trial is designed to look at safety and&#xD;
      efficacy of cenobamate adjunctive therapy as compared to placebo on PGTC seizures in subject&#xD;
      with idiopathic generalized epilepsy. Subjects will be randomized to receive either&#xD;
      cenobamate or placebo on a 1:1 basis. The study will have three periods, pre-randomization&#xD;
      period where a baseline seizure frequency is established, treatment period and follow up&#xD;
      period. The treatment period consists of a 10 week titration phase where subjects are&#xD;
      titrated slowly until they reach the target dose and a maintenance phase. During the&#xD;
      titration phase, subjects will receive 12.5 mg study drug, followed by 25 mg, 50 mg, 100 mg,&#xD;
      and 150 mg study drug every two weeks. During the maintenance phase, subjects will receive&#xD;
      the target dose of 200 mg study drug. Subjects will take their once daily dose of study drug&#xD;
      at approximately the same in the morning with or without food. If tolerability issues arise,&#xD;
      subjects can switch to evening dosing. There is also an option to down-titrate to 150 mg&#xD;
      study drug, one time only. If tolerability issues continue, subjects may be discontinued.&#xD;
      Upon completion of the maintenance phase, eligible subjects will have an opportunity to&#xD;
      enroll in an open-label safety study. Subjects who discontinue early or do not wish to&#xD;
      participate in this additional study will complete the three week follow up period. Subjects&#xD;
      may receive a one week down titration to 100 mg and return for a follow up visit 2 weeks&#xD;
      later.&#xD;
&#xD;
      Throughout the study, subjects will keep a diary containing the type and frequency of&#xD;
      seizures. This will be the primary efficacy measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">November 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure Diary</measure>
    <time_frame>28 Days</time_frame>
    <description>Daily seizure diary that contains type and frequency of seizures</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Primary Generalized Epilepsy</condition>
  <arm_group>
    <arm_group_label>Cenobamate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenobamate</intervention_name>
    <description>12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets</description>
    <arm_group_label>Cenobamate</arm_group_label>
    <other_name>YKP3089</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male or female and aged â‰¥18 years.&#xD;
&#xD;
          2. Written informed consent signed by the subject or legal guardian, prior to entering&#xD;
             the study, in accordance with the International Council for Harmonisation (ICH) Good&#xD;
             Clinical Practice (GCP) guidelines. If the written informed consent is provided by the&#xD;
             legal guardian because the subject is unable to do so, a written or verbal assent from&#xD;
             the subject must also be obtained. As required by country-specific regulations, only&#xD;
             the subject may sign the Informed Consent Form (ICF) in accordance with ICH&#xD;
             guidelines.&#xD;
&#xD;
          3. Female subjects of childbearing potential are willing to use an acceptable form of&#xD;
             birth control&#xD;
&#xD;
          4. Subject has a clinical diagnosis of PGTC seizures (with or without other subtypes of&#xD;
             generalized seizures) in the setting of idiopathic generalized epilepsy.&#xD;
&#xD;
          5. Subject experiences at least 5 PGTC seizures in 12 weeks during the Pre-Randomization&#xD;
             Period.&#xD;
&#xD;
          6. Subject has had a routine electroencephalogram (EEG) within 5 years prior to Visit1&#xD;
             (Screening/Baseline) or during the Pre-Randomization Period with&#xD;
             electroencephalographic features consistent with idiopathic generalized epilepsy;&#xD;
             other concomitant anomalies must be explained by adequate past medical history.&#xD;
&#xD;
          7. Subject has undergone computed tomography (CT) or magnetic resonance imaging (MRI)&#xD;
             within 10 years prior to Visit 1 (Screening/Baseline) or during the Pre-Randomization&#xD;
             Period that ruled out a progressive cause of epilepsy.&#xD;
&#xD;
          8. Subject is currently receiving 1 to a maximum of 3 concomitant AEDs with fixed dosing&#xD;
             regimens for a minimum of 30 days prior to Visit 1 (Screening/Baseline).&#xD;
&#xD;
               1. Benzodiazepines (except diazepam, see Exclusion Criterion No.7) taken at least&#xD;
                  once per week during the 30 days prior to Visit 1 (Screening/Baseline) for&#xD;
                  epilepsy, anxiety, or sleep disorder will be counted as 1 AED and the dosage must&#xD;
                  be continued unchanged throughout the study. Therefore, only a maximum of 2&#xD;
                  additional approved AEDs will be allowed. (See Exclusion Criterion No. 10 for&#xD;
                  intermittent benzodiazepine rescue parameters.)&#xD;
&#xD;
               2. Subjects receiving felbamate as a concomitant AED must meet the following&#xD;
                  criteria: i. Have a 2-year history of felbamate use and a history of a fixed&#xD;
                  dosing regimen for a minimum of 60 days prior to Visit 1 (Screening/Baseline).&#xD;
                  ii. No prior or known history of hepatotoxicity or hematologic disorder due to&#xD;
                  felbamate.&#xD;
&#xD;
          9. Subject with an implanted vagal nerve or deep brain stimulator will be allowed if the&#xD;
             stimulator was implanted at least 5 months prior to Visit 1 (Screening/Baseline) and&#xD;
             the stimulator parameters are not changed for 30 days prior to Visit 1 and for the&#xD;
             duration of the study.&#xD;
&#xD;
         10. Subject taking a ketogenic diet will be allowed as long as the diet has been stable&#xD;
             for at least 3 months prior to Visit 1 (Screening/Baseline) and will remain stable for&#xD;
             the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant (or planning to become pregnant during the study),&#xD;
             lactating, or breast-feeding.&#xD;
&#xD;
          2. Subject has a history o f status epilepticus that required hospitalization within 12&#xD;
             months prior to Visit 1 (Screening/Baseline).&#xD;
&#xD;
          3. Subject has PGTC seizure clusters where individual seizures cannot be counted or&#xD;
             classified.&#xD;
&#xD;
          4. Subject has a history of non-epileptic psychogenic seizures.&#xD;
&#xD;
          5. Subject has a concomitant diagnosis of Partial Onset Seizures (POS).&#xD;
&#xD;
          6. Subject has a clinical diagnosis of Lennox-Gastaut syndrome.&#xD;
&#xD;
          7. Subject is currently taking (within the 30 days prior to Visit 1 [Screening/Baseline])&#xD;
             any of the following medications: diazepam (for any reason other than as intermittent&#xD;
             benzodiazepine rescue medication), phenytoin, mephenytoin, fosphenytoin,&#xD;
             phenobarbital, primidone, ethotoin, clopidogrel, fluvoxamine, amitriptyline,&#xD;
             clomipramine, bupropion, methadone, ifosfamide, cyclophosphamide, or efavirenz.&#xD;
&#xD;
          8. Subject has participated in previous cenobamate clinical studies.&#xD;
&#xD;
          9. Subject has a history of vigabatrin use within 5months prior to Visit 1&#xD;
             (Screening/Baseline), or the subject plans to begin treatment with vigabatrin during&#xD;
             the study.&#xD;
&#xD;
             a) A subject with a history of vigabatrin use that ended more than 5 months prior to&#xD;
             Visit1 may be enrolled after documented evidence of no vigabatrin-associated&#xD;
             clinically significant abnormality in an automated visual perimetry test.&#xD;
&#xD;
         10. Subject has a history of intermittent use of rescue benzodiazepines (i.e., 1 to 2&#xD;
             doses over a 24-hour period is considered a 1-time rescue) 4 or more times within the&#xD;
             30 days prior to Visit 1 (Screening/Baseline).&#xD;
&#xD;
         11. Subject has received an investigational drug or device within 30 days prior to Visit 1&#xD;
             (Screening/Baseline).&#xD;
&#xD;
         12. Subject has a history of drug or alcohol dependency or abuse within 2 years prior to&#xD;
             Visit 1 (Screening/Baseline).&#xD;
&#xD;
         13. Subject tests positive, via urine drug screen at Visit 1 (Screening/Baseline), for&#xD;
             illicit drugs (e.g., tetrahydrocannabinol, amphetamines) or for a drug that has not&#xD;
             been prescribed (e.g., certain opiates).&#xD;
&#xD;
         14. Subject has a history of any serious drug-induced hypersensitivity reaction&#xD;
             (including, but not limited to, Stevens Johnson syndrome, toxic epidermal necrolysis,&#xD;
             or DRESS) or any drug-related rash requiring hospitalization.&#xD;
&#xD;
         15. History of AED-associated rash that involved conjunctiva or mucosae.&#xD;
&#xD;
         16. History of more than one non-serious drug-related hypersensitivity reaction that&#xD;
             required discontinuation of the medication.&#xD;
&#xD;
         17. Subject has evidence of clinically significant abnormalities or disease (e.g.,&#xD;
             psychiatric, cardiac, respiratory, gastrointestinal, hepatic [aspartate&#xD;
             aminotransferase (AST) or alanine aminotransferase (ALT) more than 2 times the upper&#xD;
             limit of normal (ULN), or total or direct bilirubin not more than ULN], or renal&#xD;
             disease) that, in the opinion of the Principal Investigator, could affect the&#xD;
             subject's safety or conduct of the study.&#xD;
&#xD;
         18. Presence of congenital short QT syndrome or relevant replicated change in QT/QTc&#xD;
             interval less than 340 msec on ECG.&#xD;
&#xD;
         19. Subject has any significant active Central Nervous System (CNS) infection,&#xD;
             demyelinating disease, degenerative neurologic disease or any CNS disease deemed to be&#xD;
             progressive during the course of the study that may confound the interpretation of the&#xD;
             study results.&#xD;
&#xD;
         20. Subject has a creatinine clearance less than 50 mL/min, as calculated by&#xD;
             Cockcroft-Gault equation.&#xD;
&#xD;
         21. Subject has an absolute neutrophil count less than 1500/ÂµL.&#xD;
&#xD;
         22. Subject has platelet count lower than 80,000/ÂµL in subjects treated with valproate.&#xD;
&#xD;
         23. Subject has a history of positive antibody/antigen test for hepatitis A, hepatitis B,&#xD;
             hepatitis C, or HIV.&#xD;
&#xD;
         24. Subject has any suicidal ideation (with intent with or without a plan) at Visit 1&#xD;
             (Screening/Baseline) or Visit 4 (Randomization) (i.e., answering YES to Question 4&#xD;
             and/or Question 5 on the Suicidal Ideation section of the C-SSRS).&#xD;
&#xD;
         25. Subject has more than 1 lifetime suicide attempt.&#xD;
&#xD;
         26. Subject is a staff member or immediate family member of study staff. Any potential&#xD;
             exception to the inclusion as well as exclusion criteria allowing de minimis&#xD;
             (clinically trivial and meaningless) variations must be approved by the Medical&#xD;
             Monitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Kamin, MD</last_name>
    <role>Study Director</role>
    <affiliation>SK Life Science, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Group LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Epilepsy and Neurology</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Epilepsy and Sleep Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology Golden Valley</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research and Innovation</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Sv. Ivan Rilski Gorna Oryahovitsa EOOD</name>
      <address>
        <city>Gorna Oryahovitsa</city>
        <state>Veliko Tarnovo</state>
        <zip>5100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Puls AD</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Lyulin EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic MHAT Tokuda EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center Neoclinic EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1408</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center Equita EOOD</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Medica Plus OOD</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cerebrovaskularni poradna, s.r.o.</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FakultnÃ­ nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forbeli s.r.o., Neurologicka ordinace</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologicka ambulance MUDr.Monika Zahumenska</name>
      <address>
        <city>ZlÃ­n</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CsongrÃ¡d Megyei EgÃ©szsÃ©gÃ¼gyi EllÃ¡to KÃ¶zpont IdeggyÃ³gyÃ¡szati OsztÃ¡ly</name>
      <address>
        <city>Hodmezovasarhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska S.J.</name>
      <address>
        <city>Ksawerow</city>
        <state>Iodzkie</state>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Medycyny Wsi im. Witolda Chodzki w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Leczenia Padaczki i Migreny</name>
      <address>
        <city>KrakÃ³w</city>
        <state>Malopolskie</state>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Warszawa Pratia s.a</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gornoslaskie Centrum Medyczne - Samodzielny Publiczny Szpital Kliniczny Number 7</name>
      <address>
        <city>Katowice</city>
        <state>Silesia</state>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Katowice</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.A. LEK A.M. Maciejowscy S.C Centrum Terapii SM</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-571</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Novo-Med</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyncentrum Clinic Sp. z.o.o</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-851</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-Mazurskie</state>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Spolka z Ograniczona Odpowiedzialnoscia Medic-R sp. k</name>
      <address>
        <city>PoznaÅ„</city>
        <state>Wielkopolskie</state>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Beata Dupejova, neurologickÃ¡ ambulncia, s.r.o</name>
      <address>
        <city>BanskÃ¡ Bystrica</city>
        <zip>974 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN MEDIC s.r.o</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KonzÃ­lium, s.r.o</name>
      <address>
        <city>Dubnica Nad VÃ¡hom</city>
        <zip>018 41</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Enterprise Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnykov of Dnipropetrovsk Regional Council, Regional Center of Psychosomatic Disorders based on Psychoneurology Department</name>
      <address>
        <city>Dnepropetrovsk</city>
        <state>Dnipropetrovsk</state>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise City Clinical Hospital No.16 of Dnipro City Council, Department of Neurology</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovsk</state>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Department of Cerebro-Vascular Diseases with Neurosurgery</name>
      <address>
        <city>Odesa</city>
        <state>Odessa</state>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise Regional Clinical Center of Neurosurgery and Neurology of Zakarpattia Regional Council, Department of Neurosurgery #2</name>
      <address>
        <city>Uzhgorod</city>
        <state>Zakarpattia</state>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise Zaporizhzhia Regional Clinical Hospital Of Zaporizhzhia Regional Council</name>
      <address>
        <city>Zaporozhye</city>
        <state>Zaporizhzhya</state>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Enterprise Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnykov of Dnipropetrovsk Regional Council</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise Prykarpattia Regional Clinical Center for Mental Health of Ivano-Frankivsk Regional Council</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Enterprise of Kharkiv Regional Council Regional Clinical Psychiatric Hospital #3</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-Profit Enterprise of Lviv Regional Council Lviv Regional Clinical Hospital, Neurological Department, Antiepileptic Center</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Medical Academy</name>
      <address>
        <city>Odessa</city>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-Profit Enterprise Odesa Regional Medical Centre of Mental Health Odesa Regional Council, Department #2</name>
      <address>
        <city>Odessa</city>
        <zip>67513</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Enterprise Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev of Poltava Regional Council</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise Ternopil Regional Clinical Psychoneurological Hospital of Ternopil Regional Council, Department of Neurology #2</name>
      <address>
        <city>Ternopil</city>
        <zip>46020</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise Vinnytsia Regional Clinical Psychoneurological Hospital named after Acad. O.I. Yushchenko of Vinnytsia Regional Council, Department of Neurology #3</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Generalized Tonic-Clonic Seizures</keyword>
  <keyword>PGTC</keyword>
  <keyword>Idiopathic Generalized Epilepsy</keyword>
  <keyword>Generalized Tonic-Clonic Seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy, Generalized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cenobamate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

